Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISRADIPINE vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Hypertension,Chronic stable angina
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Hepatic metabolism via CYP3A4 isoenzyme; undergoes extensive first-pass metabolism.
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
96%, primarily to alpha-1-acid glycoprotein and albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
2.9 L/kg (3-5 L/kg reported); clinical meaning: extensive tissue distribution, high affinity for vascular smooth muscle.
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Oral: 15-24% (first-pass effect); sustained-release: approximately 30% due to reduced presystemic metabolism.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
No dose adjustment required for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate at 2.5 mg twice daily and titrate cautiously.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
For Child-Pugh Class A or B: initiate at 2.5 mg twice daily and titrate cautiously. For Child-Pugh Class C: use isradipine with caution; consider starting at 2.5 mg once daily and adjust based on response and tolerability.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Not FDA-approved for pediatric use. Limited data: initial dose 0.05-0.15 mg/kg orally 3-4 times daily; maximum 0.8 mg/kg/day.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Initiate at 2.5 mg twice daily; titrate slowly due to increased risk of hypotension. Maximum dose usually 5 mg twice daily.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
None
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
May cause hypotension, peripheral edema, heart failure exacerbation (particularly in patients with pre-existing left ventricular dysfunction), and increased angina or myocardial infarction upon abrupt withdrawal. Use caution in patients with aortic stenosis, hepatic impairment, and in elderly patients. May cause gingival hyperplasia. Should be used with caution in patients with severe left ventricular dysfunction or heart failure.
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to isradipine or any dihydropyridine calcium channel blocker; cardiogenic shock; unstable angina; acute myocardial infarction (within first 4 weeks); severe aortic stenosis; second- or third-degree AV block (unless pacemaker present); sick sinus syndrome (unless pacemaker present); concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) due to increased risk of toxicity.
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase isradipine levels, leading to toxicity. High-fat meals may slow absorption but do not significantly alter overall effect. No other specific dietary restrictions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk. First trimester: potential for teratogenic effects. Second and third trimesters: may cause fetal hypoxia, IUGR, and preterm delivery due to maternal hypotension; also associated with decreased uterine blood flow.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Isradipine is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.14. Low concentrations are expected; based on limited data, the relative infant dose is <1% of maternal weight-adjusted dose. However, due to potential for adverse effects in nursing infants (e.g., hypotension), caution is advised. Consider benefits of breastfeeding and importance of drug to mother.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
Pregnancy may alter the pharmacokinetics of isradipine due to increased plasma volume, renal clearance, and hepatic metabolism. No specific dose adjustment guidelines are established; however, higher doses may be required to achieve therapeutic effect. Conversely, increased sensitivity to hypotensive effects may necessitate dose reduction. Individualize dosing based on blood pressure response and tolerance. Start at low doses and titrate carefully.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
Isradipine is a dihydropyridine calcium channel blocker with high vascular selectivity; it causes less negative inotropic effect than nifedipine. It is used for hypertension and has been studied for Parkinson's disease but not FDA-approved for that indication. Its short half-life (8 hours) necessitates twice-daily dosing. Monitor for peripheral edema, headache, and dizziness. Avoid grapefruit juice as it increases drug levels. Use with caution in patients with aortic stenosis or heart failure with reduced ejection fraction.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take this medication exactly as prescribed, usually twice daily.,Do not drink grapefruit juice while taking isradipine.,Avoid sudden discontinuation; consult your doctor before stopping.,Common side effects include swelling of ankles/feet, headache, and dizziness; report severe or persistent symptoms.,This medicine does not cure hypertension but helps control it; continue taking even if you feel well.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
"The combination of isradipine, a dihydropyridine calcium channel blocker, with propranolol, a non-selective beta-blocker, can result in additive negative chronotropic and inotropic effects, leading to excessive bradycardia, hypotension, and potentially heart failure. Additionally, propranolol may mask the reflex tachycardia typically induced by isradipine's vasodilation, blunting compensatory mechanisms and increasing the risk of severe hypotension. Careful monitoring and dose adjustments are necessary when coadministering these agents."
"Isradipine, a calcium channel blocker, inhibits CYP3A4-mediated metabolism of saquinavir, a protease inhibitor used in HIV therapy. This leads to significantly increased saquinavir plasma concentrations, raising the risk of dose-related toxicities such as hepatotoxicity, QT prolongation, and gastrointestinal disturbances. Conversely, saquinavir may also inhibit isradipine metabolism, potentially causing enhanced hypotensive effects and peripheral edema."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISRADIPINE vs CALAN, answered by our medical review team.
ISRADIPINE is a Calcium Channel Blocker that works by Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISRADIPINE and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISRADIPINE is: 2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISRADIPINE and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISRADIPINE is classified as Category C. Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recomme. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.